CAJ | 학술논문

目的系统评价格列美脲治疗2型糖尿病的有效性及安全性.方法计算机检索PubMed、Ovid (AIl EBM Reviews)、CNKI、万方、维普、CBM.按Cochrane系统评价的方法评价纳入研究质量,对同质研究采用RevMan 5.0进行Meta分析,对数据不能合并者,则进行描述性的定性分析.结果本研究共纳入6个RCT进行分析.由于纳入的研究所提供的数据提供不充分,未进行合并分析.6篇文献质量均为B级.研究结果显示格列美脲组降低2型糖尿病患者糖化血红蛋白、空腹和餐后血糖,以及提高餐后血浆胰岛素的效果与安慰剂组比较,其差异有统计学意义(P＜0.05).3个研究报道格列美脲组与安慰剂组比较,对空腹血浆胰岛素(FI)的影响,两组差异有统计学意义(P＜0.05),而1个研究显示两组差异无统计学意义(P＞0.05).6个RCT结果均提示格列美脲不良反应轻微.结论基于当前证据,格列美脲能降低2型糖尿病患者的糖化血红蛋白、空腹和餐后血糖,提高空腹和餐后血浆胰岛素,且不良反应轻微,是治疗2型糖尿病的有效又安全的磺脲类药物.
목적 계통평개격렬미뇨치료2형당뇨병적유효성급안전성.방법 계산궤검색PubMed、Ovid (AIl EBM Reviews)、CNKI、만방、유보、CBM.안Cochrane계통평개적방법평개납입연구질량,대동질연구채용RevMan 5.0진행Meta분석,대수거불능합병자,칙진행묘술성적정성분석.결과 본연구공납입6개RCT진행분석.유우납입적연구소제공적수거제공불충분,미진행합병분석.6편문헌질량균위B급.연구결과현시격렬미뇨조강저2형당뇨병환자당화혈홍단백、공복화찬후혈당,이급제고찬후혈장이도소적효과여안위제조비교,기차이유통계학의의(P＜0.05).3개연구보도격렬미뇨조여안위제조비교,대공복혈장이도소(FI)적영향,량조차이유통계학의의(P＜0.05),이1개연구현시량조차이무통계학의의(P＞0.05).6개RCT결과균제시격렬미뇨불량반응경미.결론 기우당전증거,격렬미뇨능강저2형당뇨병환자적당화혈홍단백、공복화찬후혈당,제고공복화찬후혈장이도소,차불량반응경미,시치료2형당뇨병적유효우안전적광뇨류약물.
Objective To assess the efficacy and safety of glimepiride for type 2 diabetes mellitus (T2DM). Methods We searched the literature from PubMed, Ovid (All EBM Reviews), CNKI, Wanfang, VIP, CBM and other databases. Evaluating the quality of the study according to Cochrane systematic reviews, Meta-analysis was performed for the results of homogeneous studies by The Cochrane Collaboration’s software RevMan 5.0, and the heterogeneous data conducted a descriptive qualitative analysis. Results Six RCTs included in the analysis and Meta-analysis was not performed due to the insufficient data (for the median or standard deviation). Six RCTs are multi-center, randomized, double-blind, placebo-controlled trials. The results showed that glimepiride groups to reduce glycosylated hemoglobin, lower fasting and postprandial blood glucose, postprandial plasma insulin enhance the efficacy were statistically significant differences (P<0.05) compared to placebo groups. Four studies informed the impact of fasting plasma insulin (FI) and 3 studies showed that the glimepiride groups improving the fasting plasma insulin (FI) were statistically significant differences (P<0.05), but 1 study showed the two groups had no significant difference (P>0.05). All studies showed minor adverse reactions of glimepiride. Conclusion Glimepiride can reduce the glycosylated hemoglobin, lower the fasting and postprandial blood glucose, improve fasting and postprandial plasma insulin for type 2 diabetes patients, and have minor adverse reactions. In a word, glimepiride is an effective and security sulfonylureas drug.